These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 27000240)

  • 1. Liposarcoma concurrence in a multiple sclerosis patient treated with interferon-beta 1b.
    Bosnjak Pasic M; Hajnsek S; Panajatovic M; Vidrih B; Bohacek I; Miskov S
    J Neurol Sci; 2016 Apr; 363():145-6. PubMed ID: 27000240
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon beta-1b-induced Sweet's syndrome in a patient with multiple sclerosis.
    Kim YJ; Lee HY; Lee JY; Yoon TY
    Int J Dermatol; 2015 Apr; 54(4):456-8. PubMed ID: 23786157
    [No Abstract]   [Full Text] [Related]  

  • 3. Interferon beta-1b-induced postmenopausal bleeding in a patient with multiple sclerosis.
    Perlman B; Heller D; Cracchiolo B
    Climacteric; 2016 Dec; 19(6):599-600. PubMed ID: 27749097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experience of application of Russian biosimilar of interferon beta-1b for treatment of pediatric multiple sclerosis].
    Popova EV; Boyko AN; Bykova OV; Nankina IG; Batysheva TT
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):73-75. PubMed ID: 27456908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous necrotic lesion: A wonderful delay adverse effect of interferon beta-1b injection for multiple sclerosis treatment.
    Mozafari N; Saffaei A; Alizadeh M; Shabani M
    J Cosmet Dermatol; 2020 Apr; 19(4):951-953. PubMed ID: 31436377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The use of beta-interferon-1b in children and adolescents with multiple sclerosis].
    Bykova OV; Kuzenkova LM; Maslova OI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):29-33. PubMed ID: 17069059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sweet syndrome associated with interferon.
    Rodriguez-Lojo R; Castiñeiras I; Juarez Y; Lueiro M; Armesto A; Fernandez-Diaz ML
    Dermatol Online J; 2014 Dec; 21(2):. PubMed ID: 25756490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
    Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Metzig C; Bauer L; Lanius V; Sandbrink R; Pohl C;
    Lancet Neurol; 2009 Nov; 8(11):987-97. PubMed ID: 19748319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe septal panniculitis in a multiple sclerosis patient treated with interferon-beta.
    Mazzon E; Guarneri C; Giacoppo S; Rifici C; Tchernev G; Polimeni G; Wollina U
    Int J Immunopathol Pharmacol; 2014; 27(4):669-74. PubMed ID: 25572749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphea secondary to interferon beta1b injection: a case and review of the literature.
    Ozlu E; Karadag AS; Akdeniz N; Uzuncakmak TK; Zemheri E; Ozkanli S
    Dermatol Online J; 2019 Apr; 25(4):. PubMed ID: 31046913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon treatment for multiple sclerosis patients in Hong Kong.
    Lau KK; Lee PO; Chan KY; Chan YW; Chin KF
    Hong Kong Med J; 2000 Jun; 6(2):221-3. PubMed ID: 10895148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis: an emerging diagnosis in Taiwan?
    Liu HC
    J Chin Med Assoc; 2004 Oct; 67(10):494-5. PubMed ID: 15648282
    [No Abstract]   [Full Text] [Related]  

  • 13. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
    Kuhle J; Hardmeier M; Disanto G; Gugleta K; Ecsedi M; Lienert C; Amato MP; Baum K; Buttmann M; Bayas A; Brassat D; Brochet B; Confavreux C; Edan G; Färkkilä M; Fredrikson S; Frontoni M; D'Hooghe M; Hutchinson M; De Keyser J; Kieseier BC; Kümpfel T; Rio J; Polman C; Roullet E; Stolz C; Vass K; Wandinger KP; Kappos L;
    Mult Scler; 2016 Apr; 22(4):533-43. PubMed ID: 26362898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Report on the Satellite Symposium "Thinking forward--critical problems of therapy. 17th Congress ECTRIMS. Dublin (Ireland), 14.09.2001].
    Cendrowski W
    Neurol Neurochir Pol; 2002; 36(1):209-11. PubMed ID: 12053612
    [No Abstract]   [Full Text] [Related]  

  • 16. [Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal].
    Khabirov FA; Babicheva NN; Khaĭbullin TI; Aver'ianova LA; Granatov EV; Akhmedova GM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(9 Pt 2):113-22. PubMed ID: 23235429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis].
    Popova EV; Boĭko AN; Davydovskaia MV; Demina TL; Kukel' TM; Lashch NIu; Popova NF; Khachanova NV; Shchur SG; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):93-6. PubMed ID: 24300821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
    Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of interferon-consensus 1, interferon-alpha 2a, and interferon-beta 1b on HLA expression and lymphoproliferation: a preclinical model for treatment of multiple sclerosis.
    Dhib-Jalbut S; Jiang H; Xia Q; Blatt L; Johnson KP; Hilt D
    J Interferon Cytokine Res; 1996 Mar; 16(3):195-200. PubMed ID: 8697141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].
    Sabanov AV; Luneva AV; Matveev NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(5):65-9. PubMed ID: 24988963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.